<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        48-100-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NORDITROPIN NORDILET 5MG\1.5ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOMATROPIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        479.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> 5 mg/1.5 ml</strong></p><p>Somatropin solution for injection</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Why have you been given Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>?</strong></p><p><strong><em>Children:</em></strong></p><p>Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> is used to treat growth failure, which is caused by:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No or very low production of growth hormone (growth hormone deficiency)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turner syndrome (a genetic problem which may affect growth)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced kidney function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short children born small for gestational age (SGA).</p><p>&nbsp;</p><p><strong><em>Adults:</em></strong></p><p>Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> is used to replace growth hormone if the production has been low since childhood or is lost in adulthood because of a tumour, treatment of a tumour or a disease that affects the gland, which produces growth hormone. If you have been treated for growth hormone deficiency during childhood, you will be retested after completion of growth. If growth hormone deficiency is confirmed, you should continue treatment.</p><p>&nbsp;</p><p><strong>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you use Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup></strong></p><p><strong><em>Do not use Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> if the growth hormone solution in the pre-filled pen is cloudy or discoloured. Check this by turning the pen upside down once or twice. </em></strong></p><p><strong><em>To avoid the risk of passing on diseases Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> is for use by one person only.</em></strong></p><p><strong><em>To make sure you get the proper dose and do not inject air, check the flow (prime the pen) before the first injection from a new Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>. Do not use Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> if a drop of growth hormone solution does not appear at the needle tip.</em></strong></p><p>&nbsp;</p><p><strong>You should not take Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> if you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are allergic to phenol or any other ingredients in this medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have had a kidney transplant.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an active tumour (cancer). Tumours must be inactive and you must have finished your anti-tumour treatment before you start your treatment with Norditropin<sup>&reg; </sup>NordiLet<sup>&reg;</sup>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an acute critical illness, e.g. open heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have stopped growing (closed epiphyses) and you do not have growth hormone deficiency.</p><p>&nbsp;</p><p><strong>Be sure to tell your physician/specialist if you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suffer from diabetes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have had cancer or another kind of tumour.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have recurrent headaches, eyesight problems, nausea, or if vomiting occurs.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have abnormal thyroid function.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Develop a limp or low-back pain as these could be signs of a curved spine (scoliosis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are over 60 years of age, or have received somatropin treatment as an adult for more than 10 years, as experience is limited.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suffer from kidney disease as your kidney function should be monitored by your physician.</p><p>&nbsp;</p><p>If any of the above applies to you, Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> may not be suitable. Your physician/specialist will give you advice.</p><p>&nbsp;</p><p>Your physician/specialist will measure your height, weight and your ability to produce growth hormone before you are prescribed Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>Can you use Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> together with other medicines?</strong></p><p>Remember to tell your physician/specialist about all the medication you are on and especially if it is:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticoids or sex steroids (for example anabolic steroids and estrogen) &ndash; your adult height may be affected if you use Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> and glucocorticoids or sex steroids at the same time</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporin (immunosuppressive) &ndash; as your dose may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insulin &ndash; as your dose may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thyroid hormone &ndash; as your dose may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticonvulsants &ndash; as your dose may need to be adjusted.</p><p>&nbsp;</p><p><strong>What should you consider if you are pregnant or breast-feeding?</strong></p><p>If you become pregnant while you are using Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>, you are recommended to stop the treatment and discuss the situation with your physician/specialist.</p><p>You are recommended not to take Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> while you are breast-feeding because somatropin might pass into your milk.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> should you take?</strong></p><p>Your physician/specialist will tell you how much Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> you should take. In children it depends on the body weight or body surface area.</p><p>&nbsp;</p><p>General recommendations for dosages are shown below.</p><p>&nbsp;</p><p><strong><em>In children with low production or lack of growth hormone:</em></strong></p><p>0.025 to 0.035 mg/kg/day or 0.7 to 1.0 mg/m&sup2;/day</p><p>&nbsp;</p><p><strong><em>In children with Turner syndrome:</em></strong></p><p>0.045 to 0.067 mg/kg/day or 1.3 to 2.0 mg/m&sup2;/day</p><p>&nbsp;</p><p><strong><em>In children with kidney diseases:</em></strong></p><p>0.050 mg/kg/day or 1.4 mg/m&sup2;/day</p><p>&nbsp;</p><p><strong><em>In children born small for gestational age (SGA):</em></strong></p><p>0.033 to 0.067 mg/kg/day or 1.0 to 2.0 mg/m&sup2;/day</p><p>&nbsp;</p><p><strong><em>In adults with low production or lack of growth hormone:</em></strong></p><p>If your growth hormone deficiency continues after completion of growth, treatment should be continued. The usual starting dose is 0.2 to 0.5 mg per day. Dose will be adjusted until you are on the right dose. If your growth hormone deficiency starts during adult life, the normal starting dose is 0.1 to 0.3 mg/day. This dose is increased each month until you receive the dose you need. The daily dose varies from person to person but is normally up to 1.0 mg/day.</p><p>Your physician/specialist will decide which daily dose you need.</p><p>&nbsp;</p><p><strong>What should you do if you forget a dose of Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>?</strong></p><p>If you forget to take a dose, take the next dose as usual &ndash; do not double your dose.</p><p>&nbsp;</p><p><strong>What should you do if you inject too much Norditropin</strong><strong><sup>&reg;</sup></strong><strong> NordiLet</strong><strong><sup>&reg;</sup></strong><strong>?</strong></p><p>If you inject too much Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>, contact your physician/specialist.</p><p>If you overdose for years, it could result in signs and symptoms of taking too much growth hormone.</p><p>&nbsp;</p><p><strong>How should you take Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>?</strong></p><p>You should inject Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> in the skin every evening just before bedtime. You should change the areas you inject so you do not harm your skin.</p><p>Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> is designed to be used with NovoFine<sup>&reg;</sup> disposable needles.</p><p>Carefully follow the instructions given in this leaflet on how to use Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>How long should you continue to take Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>?</strong></p><p>If you take Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> for growth failure because of Turner syndrome, a kidney disease or if you were born small for gestational age (SGA), you should continue until you stop growing.</p><p>If you lack growth hormone, you will benefit from it as a child and as an adult.</p><p>You may stop taking Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> at any time, but before you do this, discuss it with your physician/specialist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Effects seen in<strong> children and adults </strong>(unknown frequency):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash; wheezing; swollen eyelids, face or lips; complete collapse. Any of these may be signs of allergic reactions.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, eyesight problems, feeling sick (<em>nausea</em>) and being sick (<em>vomiting</em>). These may be signs of raised pressure in the brain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum thyroxin levels may decrease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperglycaemia (elevated levels of blood glucose).</p><p>&nbsp;</p><p>If you get any of these effects, see a physician/specialist as soon as possible. Stop using Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> until your physician/specialist says you can continue treatment.</p><p>&nbsp;</p><p>Formation of antibodies directed against somatropin has been rarely observed during Norditropin<sup>&reg;</sup> therapy.</p><p>Increased levels of liver enzymes have been reported.</p><p>&nbsp;</p><p>In uncommon (may affect up to 1 in 100) and rare (may affect up to 1 in 1,000) cases <strong>children</strong> may experience the following side effects:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, itching and pain in the area you inject</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle and joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen hands and feet due to fluid retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>&nbsp;</p><p>In children with Turner syndrome:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A few cases of increased growth of hands and feet compared to height have been observed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High doses of Norditropin<sup>&reg;</sup> may possibly increase the risk of getting ear infections.</p><p>&nbsp;</p><p><strong>Adults</strong> may experience the following:</p><p>Very common effects (may affect more than 1 in 10 adults):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen hands and feet due to fluid retention.</p><p>&nbsp;</p><p>Common effects (may affect up to 1 in 10 adults):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of skin crawling (<em>formication</em>) and numbness or pain mainly in fingers</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain and stiffness; muscle pain.</p><p>&nbsp;</p><p>Uncommon effects (may affect up to 1 in 100 adults):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Type 2 diabetes mellitus</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carpal tunnel syndrome, tingling and pain in fingers and hands</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching (can be intense) and pain in the area you inject</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle stiffness.</p><p>&nbsp;</p><p>If you experience any of these symptoms, you may need to reduce your dose. Discuss this with your physician/specialist.</p><p>&nbsp;</p><p>In very rare (may affect up to 1 in 10,000) cases the following side effects may occur in <strong>children and adults:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions.</p><p>&nbsp;</p><p><strong>You should also tell your physician/specialist if you notice any other side effects not mentioned here.</strong></p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You must store Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> solution for injection in a refrigerator (2&deg;C &ndash; 8&deg;C) in the outer carton. You must not freeze it or expose it to heat.</p><p>When in use, Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> 5 mg/1.5 ml may be kept <strong><em>either</em></strong> up to 4 weeks in a refrigerator (2&deg;C &ndash; 8&deg;C), <strong><em>or</em></strong> up to 3<strong> </strong>weeks below 25&deg;C.</p><p>Always use a new needle for each injection.</p><p>Do not keep the needle screwed onto Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> when you are not using it.</p><p>Always keep the pen cap fully closed on Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> when you are not using it.</p><p>Do not use Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> which has been frozen or exposed to excessive temperatures.</p><p>Never use Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> after the expiry date printed on the package.</p><p><strong>&nbsp;</strong></p><p><strong>Keep out of the reach and sight of children.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup> contains biosynthetic human growth hormone (somatropin), which is the active substance in Norditropin<sup>&reg;</sup> NordiLet<sup>&reg;</sup>. It is identical to the growth hormone produced in the human body. Other ingredients are: mannitol, histidine, poloxamer 188, phenol, water for injections, hydrochloric acid and sodium hydroxide.</p><p>1 mg of somatropin corresponds to 3 IU of somatropin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Norditropin® NordiLet® is a clear and colourless solution for injection in a multi-dose disposable 1.5 ml pre-filled pen. Norditropin® NordiLet® contains several doses of growth hormone solution, and a dose is injected into the skin every evening.
Norditropin® NordiLet® is available in three strengths: 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml (i.e. 3.3 mg/ml, 6.7 mg/ml and 10 mg/ml, respectively).
The pre-filled pen must be carefully disposed of when the growth hormone container is empty.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo<strong> </strong>All&eacute;</p><p>DK-2880<strong> </strong>Bagsv&aelig;rd, Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Feb/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>نورديتروبين&reg;&nbsp;نورديلِت &reg;<br />5 ملجم / 1.5 مل<br />محلول سوماتروبين للحقن</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما دواعي استعمال نورديتروبين&reg; نورديلِت &reg;؟<br />الأطفال:<br />يُستخدم نورديتروبين&reg; نورديلِت &reg;&nbsp;لعلاج قصور&nbsp; النمو الذي يسببه:<br />&bull; انعدام إنتاج هرمون النمو أو نقصه (نقص هرمون النمو)<br />&bull; متلازمة ترنر (مشكلة وراثية قد تؤثر على النمو)<br />&bull; ضعف في وظائف الكلى<br />&bull; ولادة الأطفال قصار القامة قبل إتمام عمر الحمل (SGA)<br />البالغون:<br />يتم استخدام نورديتروبين&nbsp;&reg; نورديلِت &reg; لاستبدال هرمون النمو إذا كان إنتاجه قليلاً منذ الطفولة أو تم فقده في مرحلة البلوغ بسبب الإصابة بورم أو مرض يؤثر على الغدة، التي تفرز هرمون النمو. إذا تم علاجك من نقص هرمون النمو أثناء الطفولة، فستخضع للاختبار مرة أخرى بعد اكتمال النمو. في حالة تأكيد وجود نقص بهرمون النمو، يجب عليك<br />الاستمرار في العلاج.</p><p><br />قبل استخدام نورديتروبين&reg; نورديلِت &reg;</p><p><br />لا تستخدم نورديتروبين &reg; نورديلِت &reg; إذا كان محلول هرمون النمو الموجود بالقلم المعبأ مسبقًا غير رائق أو عديم اللون. تحقق من ذلك عن طريق قلب<br />القلم مرة واحدة أو مرتين.<br />لتجنب خطر نقل الأمراض، فإن نورديتروبين&reg; نورديلِت&reg; مخصص لاستخدام شخص واحد فقط.<br />للتأكد من الحصول على الجرعة المناسبة وعدم حقن الهواء، فتحقق من التدفق (قم بتجهيز القلم)<br />قبل الحقن الأول من نورديتروبين&reg; نورديلِت &reg;الجديد: لاتستخدم نورديتروبين&reg; نورديلِت &reg; &nbsp;إذا لم&nbsp;تظهر قطرة من محلول هرمون النمو على طرف الإبرة<br /><br />يجب ألا تتناول نورديتروبين&reg; نورديلِت &reg;&nbsp;إذا كنت<br />&bull; مصابًا بالحساسية من الفينول أو أي مكونات أخرى في هذا الدواء.<br />&bull; أجريت عملية زرع كلى.<br />&bull; إذا كنت تعاني من ورم نشط السرطان. يجب أن تكون الأورام غير نشطة ويجب عليك الانتهاء&nbsp;من العلاج المضاد للأورام قبل بدء العلاج&nbsp;باستخدام نورديتروبين&reg; نورديلِت &reg;<br /><br />&bull; إذا كنت تعاني من مرض حاد مزمن، مثل جراحة القلب المفتوح أو جراحة البطن، أو رضح<br />عارض متعدد أو فشل حاد في الجهاز التنفسي.<br />&bull; إذا توقفت عن النمو (المشاش المغلق) ولا تعاني من نقص في هرمون النمو.<br />تأكد من إخبار الطبيب/الأخصائي إذا كنت:<br />&bull; تعاني من مرض السكر.<br />&bull; تعاني من مرض السرطان أو نوع آخر من الأورام.<br />&bull; تعاني من نوبات صداع متكررة، أو مشكلات في الرؤية، أو الغثيان أو في حالة حدوث قيء.<br />&bull; تعاني من اضطراب وظائف الغدة الدرقية.<br />&bull; تعاني من ألم في الأطراف أو أسفل الظهر حيث يمكن أن تكون أعراضًا لانحناء العمود الفقري (جنف العمود الفقري).<br />&bull; تبلغ من العمر أكثر من 60 عامًا أو كنت قد تلقيت علاج سوماتروبين كشخص بالغ لمدة أكثرمن 10 سنوات، لأن التجربة محدودة.<br />&bull; تعاني من مرض الكلى بحيث يجب على الطبيب مراقبة وظائف الكلى.<br />إذا كانت أي من الحالات السابقة تنطبق عليك، فقد لا يكون نورديتروبين&reg; نورديلِت &reg; مناسبًا. سيقدم الطبيب/الأخصائي لك النصيحة.</p><p>سيقوم الطبيب/الأخصائي بقياس طولك، ووزنك وقدرة جسمك على إفراز هرمون النمو قبل وصف&nbsp;نورديتروبين&reg; نورديلِت &reg; لك.</p><p><br />هل يمكنك استخدام نورديتروبين&reg; نورديلِت &reg;&nbsp;مع&nbsp; أدوية أخرى؟<br />تذكر إخبار الطبيب/الأخصائي بجميع الأدوية التي تتناولها وخاصةً إذا كانت:<br />&bull; الكورتيزونات أو هرمونات السيترويد الجنسية على سبيل المثال هرمونات السترويد البنائية والاستروجين&nbsp;&ndash; فقد يتأثر طول الشخص البالغ إذا استخدمت نورديتروبين&reg; نورديلِت&reg;&nbsp; والكورتيزونات أو هرمونات السيترويد&nbsp; الجنسية في نفس الوقت<br />&bull; السيكلوسبورين (مثبط المناعة)&nbsp;&ndash; حيث تحتاج إلى تعديل جرعتك<br />&bull; الإنسولين &ndash; حيث قد تحتاج إلى تعديل جرعتك<br />&bull; هرمون الغدة الدرقية &ndash; حيث تحتاج إلى تعديل جرعتك<br />&bull; أدوية مضادة للاختلاج&ndash; حيث تحتاج إلى تعديل جرعتك<br />ما الذي يجب عليكِ مراعاته إذا كنت حاملاً أو ترضعين رضاعة طبيعية؟<br />إذا أصبحت حاملاً وأنتِ تستخدمين نورديتروبين&reg; نورديلِت&reg;<br />فيُنصح بإيقاف العلاج ومناقشة الموقف ، مع الطبيب/الأخصائي.<br />يوصى بعدم تناول نورديتروبين &reg; نورديلِت &reg;&nbsp;أثناء الرضاعة الطبيعية لأن هرمون النمو قد ينتقل إلى الحليب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كم تبلغ جرعة نورديتروبين&reg; نورديلِت &reg;&nbsp;التي يجب تناولها؟<br />سيخبرك الطبيب/الأخصائي بجرعة&nbsp; نورديتروبين&reg; نورديلِت&reg;<br />التي يجب تناولها؟ في&nbsp;الأطفال تعتمد الجرعة على وزن الجسم أو مساحة سطح الجسم.<br />التوصيات العامة للجرعات موضحة أدناه.</p><p><br />في الأطفال المصابين بضعف إنتاج أو نقص هرمون النمو:<br />0.025 إلى 0.035 ملجم/كجم/يوم أو 0.7 إلى يوم /&sup2; 1.0 ملجم/م<br />في الأطفال المصابين بمتلازمة ترنر:<br />0.045 إلى 0.067 ملجم/كجم/يوم أو 1.3 إلى يوم /&sup2; 2.0 ملجم/م<br />في الأطفال المصابين بأمراض الكلى:<br />يوم /&sup2; 0.050 ملجم/كجم/يوم أو 1.4 ملجم/م<br />&bull; في الأطفال المولودين قبل إتمام عمر الحمل (SGA)<br />0.033 إلى 0.067 ملجم/كجم/يوم أو 1.0 إلى يوم /&sup2; 2.0 ملجم/م<br />في البالغين المصابين بضعف إنتاج أو نقص هرمون النمو:<br />إذا استمر نقص هرمون النمو بعد اكتمال النمو،<br />فيجب الاستمرار في العلاج. تتراوح الجرعة الأولية المعتادة من 0.2 إلى 0.5 ملجم كل يوم. سيتم تعديل الجرعة حتى تحصل على الجرعة المناسبة. إذا بدأ خلل هرمون النمو أثناء حياة البالغين، فإن الجرعة الأولية المعتادة تتراوح من 0.1 إلى 0.3 ملجم/يوم.<br />تزيد هذه الجرعة كل شهر حتى تحصل على الجرعة التي تحتاجها. تختلف الجرعة اليومية من شخص إلى شخص ولكنها عادةً تصل إلى 1.0 ملجم/يوم.</p><p>سيقرر الطبيب/الأخصائي مقدار الجرعة اليومية التي تحتاجها.</p><p><br />ماذا يجب عليك القيام به في حالة نسيان جرعة&nbsp;نورديتروبين&nbsp;&reg; نورديلِت &reg;<br />إذا نسيت تناول جرعة، فتناول الجرعة التالية كالمعتاد - لا تضاعف جرعتك.<br />ماذا يجب عليك القيام به في حالة حقن كمية كبيرة جدا من&nbsp;نورديتروبين&nbsp;&reg; نورديلِت &reg;<br />إذا قمت بحقن كمية زائدة من&nbsp;نورديتروبين&nbsp;&reg; نورديلِت &reg; فاتصل بالطبيب/الأخصائي. ،&reg;&nbsp;<br />إذا تناولت جرعات مفرطة لعدة سنوات، فقد يؤدي ذلك إلى ظهور إشارات وأعراض تناول كمية كبيرة جدًا من هرمون النمو.</p><p>كيف يجب أن تتناول نورديتروبين&nbsp;&reg; نورديلِت &reg;<br />يجب حقن نورديتروبين&reg; نورديلِت &reg; في الجلد كل&nbsp;مساء قبل وقت النوم مباشرةً. يجب تغيير المناطق التي تحقن بها حتى لا تضر جلدك.<br />نورديتروبين&nbsp;&reg; نورديلِت &reg; مصمم للاستخدام مع&nbsp; إبر&nbsp;NovoFine&reg;&nbsp;المعدة للاستخدام مرة واحدة.<br /><br />اتبع التعليمات الواردة في هذه النشرة بعناية حول&nbsp;كيفية استخدام نورديتروبين&reg; نورديلِت &reg;<br /><br />كم تبلغ مدة الاستمرار في تناول نورديتروبين&reg; نورديلِت&reg;<br />إذا كنت تتناول نورديتروبين &reg; نورديلِت &reg;&nbsp;لعلاج قصور النمو الناتج عن متلازمة ترنر أو مرض<br />الكلى أو إذا كنت مولودًا أصغر من العمر الحملي&nbsp;(SGA) فيجب عليك الاستمرار حتى يتوقف النمو.<br />إذا كنت تعاني من نقص في هرمون النمو، فستستفيد منه كطفل وكشخص بالغ.<br />يمكنك إيقاف تناول نورديتروبين &reg; نورديلِت &reg; في أي وقت، ولكن قبل القيام بذلك، ناقش الأمر مع الطبيب/ الأخصائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>الآثار الملحوظة في <strong>الأطفال والبالغين</strong><br />التكرار غير معروف:<br />&bull; طفح جلدي، وصعوبة التنفس وتورم الجفون أو الوجه أو الشفتين، أو هبوط حاد. قد تكون أي من هذه الأعراض إشارات على تفاعلات الحساسية.<br />&bull; الصداع ومشكلات في الرؤية، والشعور بالتعب، الغثيان&nbsp;والشعور بالمرض القيء. قد تكون هذه علامات على ارتفاع الضغط في المخ.<br />&bull; قد تقل مستويات مصل الثيروكسين.<br />&bull; فرط سكر الدم مستويات مرتفعة من سكر الدم.<br />في حالة التعرض لأي من هذه الآثار، قم بزيارة الطبيب/الأخصائي في أسرع وقت ممكن. توقف عن استخدام نورديتروبين&reg; نورديلِت &reg; حتى يخبرك&nbsp; الطبيب/الأخصائي أنه يمكنك الاستمرار في العلاج.<br />نادرًا ما تتم ملاحظة تكّون الأجسام المضادة الموجهة ضد هرمون النمو أثناء العلاج بنورديتروبين&reg;&nbsp;<br />تم الإبلاغ عن مستويات زائدة من إنزيمات الكبد.<br />في بعض الحالات غير الشائعة (قد تؤثر على شخص في كل 100 شخص)&nbsp;والحالات النادرة<br />(قد تؤثر على شخص في كل 1000 شخص)&nbsp;قد يتعرض الأطفال إلى الآثار الجانبية التالية:<br />&bull; احمرار وحكة وألم في منطقة الحقن<br />&bull; الصداع<br />&bull; ألم العضلات والمفاصل<br />&bull; تورم اليدين والقدمين بسبب الاحتفاظ بالسوائل.<br />&bull; طفح جلدي.<br />في الأطفال المصابين بمتلازمة ترنر:<br />&bull; تمت ملاحظة حالات قليلة من النمو الزائد لليدين والقدمين مقارنةً بالطول.<br />&bull; قد تؤدي الجرعات العالية من نورديتروبين&reg;&nbsp;إلى زيادة خطر الإصابة بعدوى الأذن.<br />قد يتعرض الأشخاص البالغون إلى ما يلي:<br />الآثار الشائعة جدًا (قد تؤثر على أكثر من شخص واحد في كل 10 أشخاص بالغين):<br />&bull; تورم اليدين والقدمين بسبب الاحتفاظ بالسوائل.<br />الآثار الشائعة (قد تؤثر على شخص واحد في كل 10 أشخاص بالغين):<br />&bull; الصداع<br />&bull; الشعور بتنميل الجلد التنميل&nbsp;والتخدر أو الألم في الأصابع بشكل أساسي.<br />&bull; ألم وخشونة المفاصل، وألم العضلات.<br />الآثار غير الشائعة (قد تؤثر على شخص في كل 100 شخص بالغ):<br />&bull; مرض السكر من النوع 2<br />&bull; متلازمة النفق الرسغي، والوخز والألم في الأصابع واليدين<br />&bull; الحكة يمكن أن تكون شديدة&nbsp;وألم في منطقة الحقن.<br />&bull; خشونة العضلات.<br />إذا تعرضت لأي من هذه الأعراض، فقد تحتاج إلى تقليل جرعتك. ناقش هذا الأمر مع الطبيب/ الأخصائي.</p><p>في بعض الحالات النادرة جدًا (قد توثر على شخص واحد في كل 10,000 شخص)&nbsp;قد تحدث الآثار الجانبية التالية في الأطفال والبالغين:<br />&bull; تفاعلات الحساسية.</p><p>يجب عليك أيضًا إخبار الطبيب/الأخصائي إذا لاحظت أي آثار جانبية لم يتم ذكرها هنا.</p><p>&nbsp;</p><p>للإبلاغ عن أعراض جانبية:</p><p>المركز الوطني للتيقظ والسلامة الدوائية<br />+966-11- فاكس: 2057662 o<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة o<br />+966-11- الأزمات. هاتف : 2038222<br />-2354-2334-2353- تحويلة: 2340<br />2356-2317<br />الهاتف المجاني: 8002490000 o<br />بريد الالكتروني: o<br />npc.drug@sfda.gov.sa<br />الموقع الالكتروني: o<br />www.sfda.gov.sa/npc</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب تخزين محلول نورديتروبين&nbsp;&reg; نورديلِت &reg; للحقن في الثلاجة</p><p>&nbsp;2 درجة مئوية &ndash; 8 درجات مئوية&nbsp;</p><p>في العبوة الكارتونية الخارجية. يجب ألا تجمده أو تعرضه للحرارة.<br />عند الاستخدام،&nbsp; يمكن الاحتفاظ بنورديتروبين&reg; نورديلِت&reg; 5 ملجم/ 1.5 مل إما لمدة تصل إلى 4&nbsp; أسابيع في الثلاجة &nbsp;2 درجة مئوية &ndash; 8 درجات مئوية, أو ما يصل إلى 3 أسابيع أقل من 25 درجة مئوية.<br />احرص دائمًا على استخدام إبرة جديدة في كل حقن.<br />لا تحتفظ بالإبرة مربوطة في قلم نورديتروبين&reg; نورديلِت&nbsp;&reg; عند عدم استخدامه.<br />احرص دائمًا على إبقاء غطاء القلم مغلقًا بالكاملعلى نورديتروبين&nbsp;&reg; نورديلِت &reg;<br />عند عدم استخدامه.<br />لا تستخدم نورديتروبين &reg; نورديلِت&reg; الذي تجمد أو&nbsp;تعرض لدرجات حرارة مفرطة.<br />لا تستخدم نورديتروبين&reg; نورديلِت&reg; &nbsp;بعد تاريخ&nbsp; الصلاحية المطبوع على العبوة.<br />يحفظ بعيدًا عن متناول الأطفال ونطاق رؤيتهم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحتوي نورديتروبين&reg;&nbsp; نورديلِت&reg; على هرمون النمو البشري&nbsp;سوماتروبين ، وهو المادة النشطة في&nbsp;نورديتروبين&reg;&nbsp;نورديلِت&reg;<br />يطابق هرمون النمو الذي يُفرز في جسم الإنسان.<br />العناصر الأخرى هي: مانيتول وهيستدين وبولوكسامير 188 وفينول وماء للحقن وحمض الهيدروكلوريك وهيدروكسيد الصوديوم. يعادل 1 ملجم من السوماتروبين 3 وحدات دولية من السوماتروبين.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>نورديتروبين&reg; نورديلِت&reg; هو محلول نقي عديم اللون&nbsp; في قلم معبأ مسبقًا متعدد الجرعات للاستعمال مرة واحدة تبلغ سعته 1.5 مل. يحتوي نورديتروبين&reg; نورديلِت&reg;<br />على عدة جرعات من محلول هرمون&nbsp;النمو، ويتم حقن الجرعة في الجلد كل مساء.<br />يتوفر نورديتروبين&reg;&nbsp;نورديلِت&reg; في ثلاثة تركيزات:<br />5 ملجم/ 1.5 مل، و 10 ملجم/ 1.5 مل و 15 ملجم/ 1.5 مل</p><p>أي 3.3 ملجم/مل، 6.7 ملجم/مل و 10 ملجم/مل على التوالي.<br />يجب التخلص من القلم المعبأ مسبقًا بعناية عندما تكون عبوة هرمون النمو فارغة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Novo Nordisk A/S<br />Novo All&eacute;<br />الدنمارك ،DK-2880 Bagsv&aelig;rd</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Feb/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Norditropin NordiLet 5 mg/1.5 ml, solution for injection in pre-filled pen Norditropin NordiLet 10 mg/1.5 ml, solution for injection in pre-filled pen Norditropin NordiLet 15 mg/1.5 ml, solution for injection in pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Norditropin NordiLet 5 mg/1.5 ml
One ml of solution contains 3.3 mg somatropin

Norditropin NordiLet 10 mg/1.5 ml
One ml of solution contains 6.7 mg somatropin

Norditropin NordiLet 15 mg/1.5 ml
One ml of solution contains 10 mg somatropin Somatropin (recombinant DNA origin produced in E-coli)
1mg of somatropin corresponds to 3 IU (International Unit) of somatropin For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre-filled pen 
Clear, colourless solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Children:</u></p><p>Growth failure due to growth hormone deficiency (GHD)</p><p>&nbsp;</p><p>Growth failure in girls due to gonadal dysgenesis (Turner syndrome) Growth retardation in prepubertal children due to chronic renal disease</p><p>Growth disturbance (current height SDS &lt; -2.5 and parental adjusted height SDS &lt; -1) in short children born small for gestational age (SGA), with a birth weight and/or length below -2 SD, who failed to show catch-up growth (HV SDS &lt; 0 during the last year) by 4 years of age or later.</p><p>&nbsp;</p><p><u>Adults:</u></p><p><u>Childhood onset growth hormone deficiency:</u></p><p>Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after growth completion. Testing is not required for those with more than three pituitary hormone deficits, with severe GHD due to a defined genetic cause, due to structural hypothalamic pituitary abnormalities, due to central nervous system tumours or due to high-dose cranial irradiation, or with GHD secondary to a pituitary/hypothalamic disease or insult, if measurements of serum insulin-like growth factor (IGF-I) is &lt; -2 SDS after at least four weeks off growth hormone treatment.</p><p>In all other patients an IGF-I measurement and one growth hormone stimulation test is required. <u>Adult onset growth hormone deficiency:</u></p><p>&nbsp;</p><p>Pronounced GHD in known hypothalamic-pituitary disease, cranial irradiation, and traumatic brain injury. GHD should be associated with one other deficient axis, other than prolactin. GHD should be demonstrated by one provocative test after institution of adequate replacement therapy for any other deficient axis.</p><p>&nbsp;</p><p>In adults, the insulin tolerance test is the provocative test of choice. When the insulin tolerance test is contraindicated, alternative provocative tests must be used. The combined arginine-growth hormone releasing hormone is recommended. An arginine or glucagon test may also be considered; however these tests have less established diagnostic value than the insulin tolerance test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Norditropin should only be prescribed by doctors with special knowledge of the therapeutic indication of use.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The dosage is individual and must always be adjusted in accordance with the individual&rsquo;s clinical and biochemical response to therapy.</p><p>&nbsp;</p><p><em><u>Generally recommended dosages</u></em><u>:</u></p><p>&nbsp;</p><p><em>Paediatric population</em>:</p><p><u>Growth hormone insufficiency</u></p><p>0.025-0.035 mg/kg/day or 0.7-1.0 mg/m<sup>2</sup>/day</p><p>When GHD persists after growth completion, growth hormone treatment should be continued to achieve full somatic adult development including lean body mass and bone mineral accrual (for guidance on dosing, see Replacement therapy in adults).</p><p>&nbsp;</p><p><u>Turner syndrome</u></p><p>0.045-0.067 mg/kg/day or 1.3-2.0 mg/m<sup>2</sup>/day</p><p>&nbsp;</p><p><u>Chronic renal disease</u></p><p>0.050 mg/kg/day or 1.4 mg/m<sup>2</sup>/day (see section 4.4)</p><p>&nbsp;</p><p><u>Small for Gestational Age</u></p><p>0.035 mg/kg/day or 1.0 mg/m<sup>2</sup>/day</p><p>&nbsp;</p><p>A dose of 0.035 mg/kg/day is usually recommended until final height is reached (see section 5.1). Treatment should be discontinued after the first year of treatment, if the height velocity SDS is below</p><p>+1.</p><p>Treatment should be discontinued if height velocity is &lt; 2 cm/year and, if confirmation is required, bone age is &gt; 14 years (girls) or &gt; 16 years (boys), corresponding to closure of the epiphyseal growth plates.</p><p>&nbsp;</p><p><em>Adult population:</em></p><p><u>Replacement therapy in adults</u></p><p>The dosage must be adjusted to the need of the individual patient.</p><p>In patients with childhood onset GHD, the recommended dose to restart is 0.2-0.5 mg/day with subsequent dose adjustment on the basis of IGF-I concentration determination.</p><p>In patients with adult onset GHD, it is recommended to start treatment with a low dose: 0.1-</p><p>0.3 mg/day. It is recommended to increase the dosage gradually at monthly intervals based on the clinical response and the patient&rsquo;s experience of adverse events. Serum IGF-I can be used as guidance for the dose titration. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated.</p><p>&nbsp;</p><p>Dose requirements decline with age. Maintenance dosages vary considerably from person to person, but seldom exceed 1.0 mg/day.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Generally, daily subcutaneous administration in the evening is recommended. The injection site should be varied to prevent lipoatrophy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting growth hormone (GH) therapy. Treatment should be discontinued if there is evidence of tumour growth.

Somatropin should not be used for longitudinal growth promotion in children with closed epiphyses.

Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure, or similar conditions should not be treated with somatropin (see section 4.4).

In children with chronic renal disease, treatment with Norditropin NordiLet should be discontinued at renal transplantation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Children treated with somatropin should be regularly assessed by a specialist in child growth. Somatropin treatment should always be instigated by a physician with special knowledge of growth hormone insufficiency and its treatment. This is true also for the management of Turner syndrome, chronic renal disease, and SGA. Data of final adult height following the use of Norditropin for children with chronic renal disease are not available.</p><p>&nbsp;</p><p>The maximum recommended daily dose should not be exceeded (see section 4.2).</p><p>&nbsp;</p><p>The stimulation of longitudinal growth in children can only be expected until epiphyseal closure.</p><p>&nbsp;</p><p><em><u>Children</u></em></p><p><u>Treatment of growth hormone deficiency in patients with Prader-Willi syndrome</u></p><p>There have been reports of sudden death after initiating somatropin therapy in patients with Prader- Willi syndrome, who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection.</p><p>&nbsp;</p><p><u>Small for Gestational Age</u></p><p>In short children born SGA other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment.</p><p>&nbsp;</p><p>Experience in initiating treatment in SGA patients near onset of puberty is limited. It is therefore not recommended to initiate treatment near onset of puberty.</p><p>Experience with patients with Silver-Russell syndrome is limited.</p><p>&nbsp;</p><p><u>Turner syndrome</u></p><p>Monitoring of growth of hands and feet in Turner syndrome patients treated with somatropin is recommended and a dose reduction to the lower part of the dose range should be considered if increased growth is observed.</p><p>&nbsp;</p><p>Girls with Turner syndrome generally have an increased risk of otitis media, which is why otological evaluation is recommended on at least an annual basis.</p><p>&nbsp;</p><p><u>Chronic renal disease</u></p><p>The dosage in children with chronic renal disease is individual and must be adjusted according to the individual response to therapy (see section 4.2). The growth disturbance should be clearly established before somatropin treatment by following growth on optimal treatment for renal disease over one year. Conservative management of uraemia with customary medicinal product and if needed dialysis should be maintained during somatropin therapy.</p><p>&nbsp;</p><p>Patients with chronic renal disease normally experience a decline in renal function as part of the natural course of their illness. However, as a precautionary measure during somatropin treatment, renal function should be monitored for an excessive decline, or increase in the glomerular filtration rate (which could imply hyperfiltration).</p><p>&nbsp;</p><p><u>Scoliosis</u></p><p>Scoliosis may progress in any child during rapid growth. Signs of scoliosis should be monitored during treatment. However, somatropin treatment has not been shown to increase the incidence or severity of scoliosis.</p><p>&nbsp;</p><p><u>Blood glucose and insulin</u></p><p>In Turner syndrome and SGA children it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. In patients with increased risk of diabetes mellitus (e.g. familial history of diabetes, obesity, severe insulin resistance, acanthosis nigricans) oral glucose tolerance testing (OGTT) should be performed. If overt diabetes occurs, somatropin should not be administered.</p><p>&nbsp;</p><p>Somatropin has been found to influence carbohydrate metabolism, therefore, patients should be observed for evidence of glucose intolerance.</p><p>&nbsp;</p><p><u>IGF-I</u></p><p>In Turner syndrome and SGA children it is recommended to measure the IGF-I level before start of treatment and twice a year thereafter. If on repeated measurements IGF-I levels exceed +2 SD compared to references for age and pubertal status, the dose should be reduced to achieve an IGF-I level within the normal range.</p><p>Some of the height gain obtained with treating short children born SGA with somatropin may be lost if treatment is stopped before final height is reached.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p><u>Growth hormone deficiency in adults</u></p><p>Growth hormone deficiency in adults is a lifelong disease and needs to be treated accordingly, however, experience in patients older than 60 years and in patients with more than five years of treatment in adult growth hormone deficiency is still limited.</p><p>&nbsp;</p><p><em><u>General</u></em></p><p><u>Neoplasms</u></p><p>There is no evidence for increased risk of new primary cancers in children or in adults treated with somatropin.</p><p>&nbsp;</p><p>In patients in complete remission from tumours or malignant disease, somatropin therapy has not been associated with an increased relapse rate.</p><p>&nbsp;</p><p>An overall slight increase in second neoplasms has been observed in childhood cancer survivors treated with growth hormone, with the most frequent being intracranial tumours. The dominant risk factor for second neoplasms seems to be prior exposure to radiation.</p><p>&nbsp;</p><p>Patients who have achieved complete remission of malignant disease should be followed closely for relapse after commencement of somatropin therapy.</p><p>&nbsp;</p><p><u>Leukemia</u></p><p>Leukaemia has been reported in a small number of growth hormone deficient patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in somatropin recipients without predisposition factors.</p><p>&nbsp;</p><p><u>Benign intracranial hypertension</u></p><p>In the event of severe or recurrent headache, visual problems, nausea, and/or vomiting, a funduscopy for papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranial hypertension should be considered and if appropriate the somatropin treatment should be discontinued.</p><p>&nbsp;</p><p>At present there is insufficient evidence to guide clinical decision making in patients with resolved intracranial hypertension. If somatropin treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary.</p><p>&nbsp;</p><p>Patients with growth hormone deficiency secondary to an intracranial lesion should be examined frequently for progression or recurrence of the underlying disease process.</p><p>&nbsp;</p><p><u>Thyroid function</u></p><p>Somatropin increases the extrathyroidal conversion of T4 to T3 and may, as such, unmask incipient hypothyroidism. Monitoring of thyroid function should therefore be conducted in all patients. In patients with hypopituitarism, standard replacement therapy must be closely monitored when somatropin therapy is administered.</p><p>&nbsp;</p><p>In patients with a pituitary disease in progression, hypothyroidism may develop.</p><p>Patients with Turner syndrome have an increased risk of developing primary hypothyroidism associated with anti-thyroid antibodies. As hypothyroidism interferes with the response to somatropin therapy patients should have their thyroid function tested regularly, and should receive replacement therapy with thyroid hormone when indicated.</p><p>&nbsp;</p><p><u>Insulin sensitivity</u></p><p>Because somatropin may reduce insulin sensitivity, patients should be monitored for evidence of glucose intolerance (see section 4.5). For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin containing product therapy is instituted. Patients with diabetes or glucose intolerance should be monitored closely during somatropin therapy.</p><p>&nbsp;</p><p><u>Antibodies</u></p><p>As with all somatropin containing products, a small percentage of patients may develop antibodies to somatropin. The binding capacity of these antibodies is low and there is no effect on growth rate.</p><p>Testing for antibodies to somatropin should be carried out in any patient who fails to respond to therapy.</p><p>&nbsp;</p><p><em><u>Clinical trial experience</u></em></p><p>Two placebo-controlled clinical trials of patients in intensive care units have demonstrated an increased mortality among patients suffering from acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure, who were treated with somatropin in high doses (5.3 - 8 mg/day). The safety of continuing somatropin treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with somatropin in patients having acute critical illnesses should be weighed against the potential risk.</p><p>&nbsp;</p><p>One open-label, randomised clinical trial (dose range 0.045-0.090 mg/kg/day) with patients with Turner syndrome indicated a tendency for a dose-dependent risk of otitis externa and otitis media. The increase in ear infections did not result in more ear operations/tube insertions compared to the lower dose group in the trial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant treatment with glucocorticoids inhibits the growth-promoting effects of somatropin containing products. Patients with ACTH deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on somatropin.</p><p>&nbsp;</p><p>Data from an interaction study performed in growth hormone deficient adults suggest that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P450 3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.</p><p>&nbsp;</p><p>The effect of somatropin on final height can also be influenced by additional therapy with other hormones, e.g. gonadotrophin, anabolic steroids, estrogen, and thyroid hormone.</p><p>&nbsp;</p><p>In insulin treated patients adjustment of insulin dose may be needed after initiation of somatropin treatment (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Animal studies are insufficient with regard to effects on pregnancy, embryofoetal development, parturition, or postnatal development. No clinical data on exposed pregnancies are available.</p><p>Therefore, somatropin containing products are not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>There have been no clinical studies conducted with somatropin containing products in breast-feeding women. It is not known whether somatropin is excreted in human milk. Therefore caution should be exercised when somatropin containing products are administered to breast-feeding women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Fertility studies with Norditropin have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Norditropin NordiLet has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Growth hormone deficient patients are characterised by extracellular volume deficit. When treatment with somatropin is initiated, this deficit is corrected. Fluid retention with peripheral oedema may occur especially in adults. Carpal tunnel syndrome is uncommon, but may be seen in adults. The symptoms are usually transient, dose dependent and may require transient dose reduction.</p><p>Mild arthralgia, muscle pain, and paresthesia may also occur, but are usually self-limiting. Adverse reactions in children are uncommon or rare.</p><p>Clinical trial experience:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>System organ classes</p></td><td style="vertical-align:top"><p>Very common (2: 1/10)</p></td><td style="vertical-align:top"><p>Common (2: 1/100 to</p><p>&lt; 1/10)</p></td><td style="vertical-align:top"><p>Uncommon (2: 1/1,000 to</p><p>&lt; 1/100)</p></td><td style="vertical-align:top"><p>Rare</p><p>(2: 1/10,000 to</p><p>&lt; 1/1,000)</p></td></tr><tr><td style="vertical-align:top"><p><em><u>Metabolism and</u> <u>nutrition disorders</u></em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>In adults Diabetes mellitus type 2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em><u>Nervous system</u> <u>disorders</u></em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>In adults headache and paraesthesia</p></td><td style="vertical-align:top"><p>In adults carpal tunnel syndrome. In children</p><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em><u>Skin and</u></em></p><p><em><u>subcutaneous tissue</u> <u>disorders</u></em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>In adults pruritus</p></td><td style="vertical-align:top"><p>In children rash</p></td></tr><tr><td style="vertical-align:top"><p><em><u>Musculoskeletal,</u> <u>connective tissue</u> <u>disorders</u></em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>In adults arthralgia, joint stiffness, and</p><p>myalgia</p></td><td style="vertical-align:top"><p>In adults muscle stiffness</p></td><td style="vertical-align:top"><p>In children arthralgia and myalgia</p></td></tr><tr><td style="vertical-align:top"><p><em><u>General disorders</u> <u>and administration</u> <u>site conditions</u></em></p></td><td style="vertical-align:top"><p>In adults peripheral oedema (see text above)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>In adults and children injection site pain. In children injection</p><p>site reaction</p></td><td style="vertical-align:top"><p>In children peripheral oedema</p></td></tr></tbody></table><p>&nbsp;</p><p>In children with Turner syndrome increased growth of hands and feet has been reported during somatropin therapy.</p><p>&nbsp;</p><p>A tendency for increased incidence of otitis media in Turner syndrome patients treated with high doses of Norditropin has been observed in one open-label randomised clinical trial. However, the increase in ear infections did not result in more ear operations/tube insertions compared to the lower dose group in the trial.</p><p>&nbsp;</p><p><u>Post-marketing experience:</u></p><p>&nbsp;</p><p>In addition to the above mentioned adverse drug reactions, those presented below have been spontaneously reported and are by an overall judgement considered possibly related to Norditropin treatment. Frequences of these adverse events cannot be estimated from the available data:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Neoplasms benign and malignant (including cysts and polyps): Leukaemia has been reported in a small number of growth hormone deficiency patients (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Immune system disorders: Hypersensitivity (see section 4.3). Formation of antibodies directed against somatropin. The titres and binding capacities of these antibodies have been very low and have not interfered with the growth response to Norditropin administration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Endocrine disorders: Hypothyroidism. Decrease in serum thyroxin levels (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Metabolism and nutrition disorders: Hyperglycemia (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Nervous system disorders: Benign intracranial hypertension (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal and connective tissue disorders: Slipped capital femoral epiphysis. Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders. Legg-Calv&eacute;-Perthes disease. Legg-Calv&eacute;-Perthes disease may occur more frequently in patients with short stature</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Investigations: Increase in blood alkaline phosphatase level.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via The National&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacovigilanceand Drug Safety Centre (NPC).</p><p>&nbsp;</p><p><strong>TO REPORTS ANY SIDE EFFECT(S):</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t202"
  coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:66.6pt;margin-top:8.35pt;width:462.15pt;height:81.15pt;z-index:-251658752;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.35pt;margin-right:176.5pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;text-indent:
     1.4pt;line-height:95%'><span lang=EN-US style='font-family:"Calibri",sans-serif;
     mso-hansi-font-family:"Times New Roman"'>The National Pharmacovigilance
     and Drug Safety Centre (NPC) o Fax: +966-11-205-7662<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.1pt;margin-bottom:.0001pt'><span lang=EN-US
     style='font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman"'>o
     Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-left:13.5pt;text-indent:-8.45pt;
     mso-list:l0 level1 lfo1;tab-stops:13.55pt'><![if !supportLists]><span
     lang=EN-US style='font-family:"Calibri",sans-serif;mso-fareast-font-family:
     Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US style='font-family:"Calibri",sans-serif'>Toll
     free phone:<span style='letter-spacing:-.05pt'> </span>8002490000<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-left:13.5pt;text-indent:-8.45pt;
     mso-list:l0 level1 lfo1;tab-stops:13.55pt'><![if !supportLists]><span
     lang=EN-US style='font-family:"Calibri",sans-serif;mso-fareast-font-family:
     Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US style='font-family:"Calibri",sans-serif'>E-mail:<span
     style='letter-spacing:-.1pt'> </span></span><span lang=EN-US><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"Calibri",sans-serif;
     color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a></span><span
     lang=EN-US style='font-family:"Calibri",sans-serif'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:13.55pt;margin-bottom:.0001pt;text-indent:-8.45pt;
     mso-list:l0 level1 lfo1;tab-stops:13.6pt'><![if !supportLists]><span
     lang=EN-US style='font-family:"Calibri",sans-serif;mso-fareast-font-family:
     Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US style='font-family:"Calibri",sans-serif'>Website:<span
     style='letter-spacing:-.1pt'> </span></span><span lang=EN-US><a
     href="http://www.sfda.gov.sa/npc"><span style='font-family:"Calibri",sans-serif;
     color:windowtext;text-decoration:none;text-underline:none'>www.sfda.gov.sa/npc</span></a></span><span
     lang=EN-US style='font-family:"Calibri",sans-serif'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;<p>&nbsp;</p></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute overdosage can lead to low blood glucose levels initially, followed by high blood glucose levels. These decreased glucose levels have been detected biochemically, but without clinical signs of hypoglycemia. Long-term overdosage could result in signs and symptoms consistent with the known effects of human growth hormone excess.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Somatropin and somatropin agonists. ATC: H01AC01. <u>Mechanism of action</u></p><p>Norditropin NordiLet contains somatropin, which is human growth hormone produced by recombinant DNA-technology. It is an anabolic peptide of 191 amino acids stabilized by two disulphide bridges with a molecular weight of approximately 22,000 Daltons.</p><p>&nbsp;</p><p>The major effects of somatropin are stimulation of skeletal and somatic growth and pronounced influence on the body&rsquo;s metabolic processes.</p><p>&nbsp;</p><p><u>Pharmacodynamic effect</u></p><p>&nbsp;</p><p>When growth hormone deficiency is treated a normalisation of body composition takes place resulting in an increase in lean body mass and a decrease in fat mass.</p><p>Somatropin exerts most of its actions through insulin-like growth factor I (IGF-I), which are produced in tissues throughout the body, but predominantly by the liver.</p><p>More than 90% of IGF-I is bound to binding proteins (IGFBPs) of which IGFBP-3 is the most important.</p><p>&nbsp;</p><p>A lipolytic and protein sparing effect of the hormone becomes of particular importance during stress.</p><p>&nbsp;</p><p>Somatropin also increases bone turnover indicated by an increase in plasma levels of biochemical bone markers. In adults bone mass is slightly decreased during the initial months of treatment due to more pronounced bone resorption, however, bone mass increases with prolonged treatment.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>In clinical trials in short children born SGA doses of 0.033 and 0.067 mg/kg/day have been used for treatment until final height. In 56 patients who were continuously treated and have reached (near) final height, the mean change from height at start of treatment was +1.90 SDS (0.033 mg/kg/day) and</p><p>+2.19 SDS (0.067 mg/kg/day). Literature data from untreated SGA children without early spontaneous catch-up suggest a late growth of 0.5 SDS. Long-term safety data are still limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>I.v. infusion of Norditropin (33 ng/kg/min for 3 hours) to nine growth hormone deficient patients, gave the following results: serum half-time of 21.1 &plusmn; 1.7 min., metabolic clearance rate of 2.33 &plusmn; 0.58 ml/ kg/min. and a distribution space of 67.6 &plusmn; 14.6 ml/kg.</p><p>&nbsp;</p><p>S.c. injection of Norditropin SimpleXx (Norditropin SimpleXx is the cartridge containing the solution for injection in Norditropin NordiLet) 2.5 mg/m<sup>2</sup> in 31 healthy subjects (with endogenous somatropin suppressed by continuous infusion of somatostatin) gave the following results:</p><p>Maximal concentration of human growth hormone (42-46 ng/ml) after approximately 4 hours. Thereafter human growth hormone declined with a half-life of approximately 2.6 hours.</p><p>In addition the different strengths of Norditropin SimpleXx were demonstrated to be bioequivalent to each other and to conventional Norditropin after subcutaneous injection to healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The general pharmacological effects on the CNS, cardiovascular and respiratory systems following administration of Norditropin SimpleXx with and without forced degradation were investigated in mice and rats; renal function was also evaluated. The degraded product showed no difference in effect when compared with Norditropin SimpleXx and Norditropin. All three preparations showed the expected dose dependent decrease in urine volume and retention of sodium and chloride ions.</p><p>&nbsp;</p><p>In rats, similar pharmacokinetics has been demonstrated between Norditropin SimpleXx and Norditropin. Degraded Norditropin SimpleXx has also been demonstrated to be bioequivalent with Norditropin SimpleXx.</p><p>&nbsp;</p><p>Single and repeated dose toxicity and local tolerance studies of Norditropin SimpleXx or the degraded product did not reveal any toxic effect or damage to the muscle tissue.</p><p>&nbsp;</p><p>The toxicity of poloxamer 188 has been tested in mice, rats, rabbits, and dogs and no findings of toxicological relevance were revealed.</p><p>Poloxamer 188 was rapidly absorbed from the injection site with no significant retention of the dose at the site of injection. Poloxamer 188 was excreted primarily via the urine.</p><p>&nbsp;</p><p>Norditropin SimpleXx is the cartridge containing the solution for injection in Norditropin NordiLet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Histidine</p><p>Poloxamer 188</p><p>Phenol</p><p>Water for injection</p><p>Hydrochloric acid for pH adjustment</p><p>Sodium hydroxide for pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After first opening: Store for a maximum of 4 weeks in a refrigerator (2C – 8C).
Alternatively, the medicinal product may be stored for a maximum of 3 weeks below 25C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C) in the outer carton, in order to protect it from light. Do not freeze. For storage conditions after first opening of the medicinal product, see section 6.3.Do not freeze.</p><p>&nbsp;</p><p>When in use, always replace the pen cap on the Norditropin NordiLet pre-filled pen after each injection. Always use a new needle for each injection.</p><p>The needle must not be screwed onto the pre-filled pen when it is not in use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Norditropin NordiLet 5 mg/1.5 ml</u> is a multi-dose disposable pre-filled pen, which consists of a cartridge (Type I colourless glass) permanently sealed in a plastic pen-injector. The cartridge is closed at the bottom with a rubber stopper (Type I rubber closures) shaped as a plunger and at the top with a laminated rubber stopper (Type I rubber closures) shaped as a disc and sealed with an aluminium cap. The push-button on the pen-injector is coloured orange. Pack sizes of 1 pre-filled pen.</p><p>&nbsp;</p><p><u>Norditropin NordiLet 10 mg/1.5 ml</u> is a multi-dose disposable pre-filled pen, which consists of a cartridge (Type I colourless glass) permanently sealed in a plastic pen-injector. The cartridge is closed at the bottom with a rubber stopper (Type I rubber closures) shaped as a plunger and at the top with a laminated rubber stopper (Type I rubber closures) shaped as a disc and sealed with an aluminium cap. The push-button on the pen-injector is coloured blue. Pack sizes of 1 pre-filled pen.</p><p>&nbsp;</p><p><u>Norditropin NordiLet 15 mg/1.5 ml</u> is a multi-dose disposable pre-filled pen, which consists of a cartridge (Type I colourless glass) permanently sealed in a plastic pen-injector. The cartridge is closed at the bottom with a rubber stopper (Type I rubber closures) shaped as a plunger and at the top with a laminated rubber stopper (Type I rubber closures) shaped as a disc and sealed with an aluminium cap. The push-button on the pen-injector is coloured green. Pack sizes of 1 pre-filled pen.</p><p>&nbsp;</p><p>The pre-filled pen is packed in a carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Norditropin NordiLet is a pre-filled pen designed to be used with NovoFine needles. The dose is delivered in clicks. NordiLet delivers 1 &ndash; 29 clicks in increments of 1 click for each injection. The dose per click is the following for each strength: 0.0667 mg (5 mg/1.5 ml), 0.1333 mg (10 mg/1.5 ml) and 0.2000 mg (15 mg/1.5 ml). In the package leaflet for each strength a range of doses in mg per number of clicks is given in a conversion table.</p><p>&nbsp;</p><p>To ensure proper dosing and avoid injection of air, check the growth hormoneflow (prime) before the first injection. Do not use Norditropin NordiLet if a drop of growth hormone does not appear at the needle tip. A dose is dialled in clicks by turning the pen cap. The dialled dose is checked by addition of the figure on the pen cap scale and the figure on the push button scale. The push button is pressed to inject the dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>Norditropin NordiLet should not be shaken vigorously at any time.</p><p>&nbsp;</p><p>Do not use Norditropin NordiLet if the growth hormone solution for injection is cloudy or discoloured. Check this by turning the pen upside down once or twice.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
 Novo Allé
DK-2880 Bagsværd 
Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>